Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1010 seasonal influenza vaccine in adults
NCT05827978Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Apr 2023
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of mRNA-1010 in seasonal influenza (2 arms), sponsored by Moderna Inc. Primary endpoints: Geometric Mean Titer of Anti-Hemagglutinin Antibody Levels at Day 29, Percentage of Participants Reaching Seroconversion at Day 29 and 3 more. Started Apr 2023; status: completed.
02
Drugs
mRNA-1010
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT05827978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827978.